Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.04 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including oligodendrocytes; strongest in bergmann glia | 0.75 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 5640
Sealed predictions
- PHYHIPL in dopamine neurons, braak+0.21 (p 0.586) → +0.11 (p 0.787)receipt 5649
- PHYHIPL in oligodendrocytes, braak+0.00 (p 1.000) → +0.41 (p 0.272)receipt 5648
Swarm cases
receipt 5649: PHYHIPL in dopamine neurons, braak
- power
- full sample +0.00 (p 0.990, n 18), 95% CI -0.46 to +0.47. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.04 (p 0.881, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.04 (p 0.888, n 18). could be the mix.
- skeptic
- leave-one-out range -0.12 to +0.13, sign flips 10; without severely affected donors +0.00 (p 0.990, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for PHYHIPL in dopamine neurons.
case closed: nothing better to follow up.
receipt 5648: PHYHIPL in oligodendrocytes, braak
- power
- full sample +0.24 (p 0.332, n 18), 95% CI -0.25 to +0.64. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.24 (p 0.332, n 18). does not hold up.
- composition
- oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.38 (p 0.120, n 18). could be the mix.
- skeptic
- leave-one-out range +0.14 to +0.39, sign flips 0; without severely affected donors +0.24 (p 0.332, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for PHYHIPL in oligodendrocytes.
case closed: nothing better to follow up.
Receipts
loading the receipts